Company intelligence / Profile preview
Sunny Pharmtech
- Ownership
- Private
- Employees
- ~144
- Development stage
- Commercial
Overview
Sunny Pharmtech develops, manufactures, and commercializes niche generic drugs—including oral solids, injectables, ointments—and provides CDMO/CMO services. It has received multiple US FDA ANDA approvals since its first approval in 2017. Its facilities have passed both Taiwan FDA and US FDA inspections. The company focuses on high-value generics with complex or special dosage forms for global markets.
- Therapeutic areas
- Infectious DiseasesOncologyHematologyOtherWomen's Health
- Modalities
- Small moleculeInjectable drug productsOral dosage formsOintment (topical)Vitamin injection (biologic/small molecule)Capsule/tablet (oral solid dose)
- Industry
- Biotech
Drug pipeline
12 assets11 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Sunny Pharmtech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sunny Pharmtech.